ID   RIL175-R
AC   CVCL_B7TN
DR   Wikidata; Q114312789
RX   DOI=10.5282/edoc.26548;
RX   PubMed=32652772;
CC   Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53.
CC   Selected for resistance to: ChEBI; CHEBI_50924; Sorafenib (Nexavar).
CC   Genetic integration: Method=Transfection/transduction; Gene=HGNC; HGNC:5173; HRAS (Note=With p.Gly12Val).
CC   Breed/subspecies: C57BL/6.
DI   NCIt; C38756; Hepatocellular carcinoma of the mouse
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_B7TK ! RIL-175
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 19-12-24; Version: 6
//
RX   DOI=10.5282/edoc.26548;
RA   Messner M.;
RT   "Sorafenib resistance of hepatocellular carcinoma: antibiotics second-
RT   line to sorafenib therapy inhibit mitochondrial biogenesis and prevent
RT   tumor growth resumption.";
RL   Thesis PhD (2020); Ludwig Maximilians University of Munich; Munich; Germany.
//
RX   PubMed=32652772; DOI=10.1096/fj.202001128R;
RA   Messner M., Schmitt S., Ardelt M.A., Frohlich T., Muller M., Pein H.,
RA   Huber-Cantonati P., Ortler C., Koenig L.M., Zobel L., Koeberle A.,
RA   Arnold G.J., Rothenfusser S., Kiemer A.K., Gerbes A.L., Zischka H.,
RA   Vollmar A.M., Pachmayr J.;
RT   "Metabolic implication of tigecycline as an efficacious second-line
RT   treatment for sorafenib-resistant hepatocellular carcinoma.";
RL   FASEB J. 34:11860-11882(2020).
//